Recently, therapies utilizing APP inhibitors, ROS inhibitors, anti-inflammatory, and anti-tau factors have been proposed as potential treatments for AD (Scarpini et al., 2003; Cummings et al., 2019; Xie et al., 2020). This evidence concerns the gene MAPT and Alzheimer disease.